Ind-Swift Laboratories Limited has informed the Exchange regarding 'Disclosure under Regulation 7(2) read with Regulation 6(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015 '.
INDSWFTLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Essix Biosciences Limited, a promoter group entity of Ind-Swift Laboratories, has acquired 11,00,000 equity shares by converting fully convertible warrants into equity shares on a preferential allotment basis. The conversion took place on July 2, 2025, at an issue price of Rs. 121 per share, taking the total transaction value to about Rs. 13.31 crore. As a result, Essix Biosciences' holding in the company increased from 33.31% to 34.86% of the post-allotment paid-up equity share capital. The company's total equity share count rose from 6.06 crore to 6.72 crore shares following this allotment.
This is a positive signal of promoter confidence, as the promoter group has chosen to convert warrants into actual equity, increasing its stake in the company. It also strengthens the promoter's commitment and slightly dilutes non-promoter shareholders' proportional holding.